Retinal biomarkers represent a promising frontier in the diagnosis and monitoring of neurodegenerative diseases. The retina, as an embryological extension of the central nervous system, offers a unique window into brain pathology through non-invasive imaging. This page synthesizes current knowledge on retinal biomarkers across major neurodegenerative conditions, including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington's disease (HD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB)[1][2].
The convergence of ophthalmological imaging advances and neuroscience discoveries has accelerated the development of retinal biomarkers from research tools to potential clinical applications. Unlike invasive CSF sampling or expensive PET imaging, retinal assessment provides a cost-effective, repeatable, and accessible approach to biomarker discovery that could transform early diagnosis and therapeutic monitoring in neurodegeneration[3].
The retina shares developmental origin, cellular composition, and vascular properties with the brain, making it an ideal surrogate for CNS pathology[4]. During embryonic development, the retina develops from the diencephalon, establishing permanent anatomical and functional connections with the brain through the optic nerve. This shared lineage means that pathological processes affecting the brain frequently manifest in the retina, providing clinicians with a direct observable window into CNS degeneration.
Unlike the brain, the retina is directly accessible to non-invasive imaging, enabling repeated measurements without risk or discomfort. Key structural and functional changes in the retina mirror pathological processes occurring in the brain:
The retinal vasculature, particularly the microvascular networks visible with optical coherence tomography angiography (OCTA), provides critical information about cerebral vascular health and the blood-retinal barrier integrity that often mirrors blood-brain barrier status in neurodegeneration[5].
Multiple imaging technologies have been applied to retinal biomarker detection, each providing complementary information about different aspects of retinal pathology:
| Modality | Key Measurements | Clinical Utility | Limitations |
|---|---|---|---|
| OCT | Retinal layer thickness (μm) | Structural neurodegeneration | Resolution limits |
| OCTA | Vessel density, FAZ area | Vascular dysfunction | Motion artifacts |
| Fundus photography | Optic disc, retinal vasculature | Screening | Limited quantification |
| Hyperspectral imaging | Amyloid/tau detection | Protein deposition | Validation pending |
| Adaptive optics | Individual cell imaging | Research | Cost and complexity |
| Fluorescence imaging | Amyloid, lipofuscin | Protein deposition | Invasive contrast agents |
Optical Coherence Tomography (OCT) has become the cornerstone of retinal biomarker assessment, providing high-resolution cross-sectional images of retinal layers with axial resolution of 3-5 μm. Spectral-domain OCT (SD-OCT) and swept-source OCT (SS-OCT) enable quantification of subtle layer thickness changes that correlate with neurodegeneration[6].
Optical Coherence Tomography Angiography (OCTA) represents a significant advancement, allowing non-invasive visualization of retinal and choroidal vasculature without dye injection. By detecting motion contrast from moving red blood cells, OCTA provides detailed maps of the superficial and deep capillary plexuses, enabling quantification of vessel density, foveal avascular zone (FAZ) metrics, and capillary dropout patterns that reflect microvascular dysfunction in neurodegeneration[7].
Retinal changes in AD reflect the underlying amyloid and tau pathology affecting the brain. The Retina in AD study and subsequent multi-center investigations have established a robust association between retinal structural changes and cognitive impairment[8].
Retinal Nerve Fiber Layer (RNFL):
Ganglion Cell Layer (GCL):
Macular Measurements:
OCTA reveals significant microvascular changes in AD that parallel cerebral small vessel disease[11]:
The vascular changes in AD extend beyond simple density reduction to include altered vascular branching patterns, increased vessel tortuosity, and reduced perfusion in the deep capillary plexus that may reflect underlying cerebral amyloid angiopathy[12].
Retinal Amyloid-Beta:
Retinal Tau:
Retinal changes in PD reflect dopaminergic neurodegeneration, particularly affecting the inner retinal layers where dopaminergic amacrine cells reside[14]:
Inner Retinal Layer Thinning:
Correlation with Clinical Features:
OCTA findings in PD demonstrate microvascular dysfunction that may precede structural changes[15]:
Retinal biomarkers in ALS extend beyond the motor system, reflecting the multisystem nature of the disease[16]:
FTD shows distinct patterns from AD that may aid differential diagnosis[17]:
Retinal biomarkers in HD show remarkable correlation with genetic burden[18]:
Emerging evidence suggests MSA shows distinct retinal signatures[19]:
DLB demonstrates retinal changes that may complement established biomarkers[20]:
The "Alzheimer's Eye Test" concept refers to comprehensive retinal evaluation as a potential screening tool for AD. This multimodal approach combines multiple imaging and functional assessments to maximize diagnostic accuracy[21]:
Studies demonstrate high diagnostic accuracy with multimodal approaches[22]:
Despite promising results, significant challenges remain:
| Disease | Key Retinal Biomarker | Sensitivity | Specificity |
|---|---|---|---|
| AD | RNFL + GC-IPL thinning | 70-85% | 75-85% |
| PD | Inner retinal thinning | 60-75% | 70-80% |
| ALS | Macular thinning | 50-65% | Variable |
| HD | Temporal RNFL thinning | 55-70% | Variable |
| FTD | Diffuse RNFL thinning | 45-60% | Variable |
| MSA | GCL thinning + vascular | 55-70% | 70-80% |
Serial OCT measurements provide valuable information for tracking neurodegeneration[23]:
Retinal biomarkers can monitor treatment effects across therapeutic modalities[24]:
The unique characteristics of retinal assessment make it highly attractive for neurodegeneration biomarker applications[25]:
Despite significant promise, retinal biomarkers face several challenges[26]:
Multimodal approaches combining retinal biomarkers with other assessment modalities enhance diagnostic accuracy[27]:
Hyperspectral imaging enables label-free detection of retinal amyloid and tau deposits through distinctive spectral signatures[28]. This technology shows promise for:
Adaptive optics corrected wavefront sensor imaging allows visualization of individual photoreceptors and retinal ganglion cells in vivo[29]. Applications include:
Machine learning approaches applied to retinal imaging show exceptional promise[30]:
Development of portable OCT devices expands access to retinal biomarker assessment[31]:
Recent advances in retinal biomarkers for neurodegeneration demonstrate accelerating progress:
The field of retinal biomarkers for neurodegenerative diseases has matured considerably, with robust evidence supporting the clinical utility of retinal imaging for diagnosis and monitoring. The convergence of advanced imaging technologies, artificial intelligence analysis, and integration with fluid biomarkers positions retinal assessment as a key component of multimodal neurodegeneration evaluation.
Current evidence supports the use of OCT and OCTA measurements as valuable adjuncts to traditional biomarkers, particularly in settings where MRI or PET access is limited. The non-invasive, repeatable, and cost-effective nature of retinal imaging makes it suitable for screening applications and longitudinal monitoring that would be impractical with more expensive modalities.
Several key developments are expected to accelerate clinical translation: standardization of acquisition and analysis protocols across devices and sites, validation of retinal endpoints in large-scale clinical trials, and integration of AI-powered analysis into clinical workflows. The combination of retinal biomarkers with plasma and CSF measures offers the most promise for comprehensive biomarker panels that can support early diagnosis, disease staging, and therapeutic monitoring.
As the global population ages and neurodegenerative diseases become increasingly prevalent, accessible biomarker platforms like retinal imaging will become essential tools for early detection and intervention. The retina truly serves as a window to the brain, and continued investment in this field promises to transform neurological care by enabling earlier diagnosis and more effective treatments for the millions affected by these devastating conditions.
Key Takeaways:
London et al. The eye as a window to the brain. Nature Reviews Neurology. 2013. ↩︎
Chan VTT et al. 'Retinal biomarkers in neurodegenerative diseases: Current status and future perspectives'. Progress in Retinal and Eye Research. 2024. ↩︎
Koronyo-Hamaoui M et al. 'Retinal biomarkers for Alzheimer''s disease: From bench to bedside'. Alzheimer's & Dementia. 2023. ↩︎
Hinton DR et al. 'Retinal degeneration in Alzheimer''s disease: Common pathways and emerging biomarkers'. Acta Neuropathologica. 2024. ↩︎
Yoon SP et al. Retinal microvascular abnormalities in Alzheimer's disease. JAMA Ophthalmology. 2023. ↩︎
den Haan J et al. 'Retinal thickness measurements in Alzheimer''s disease: A systematic review and meta-analysis'. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2017. ↩︎
Bulut M et al. Evaluation of optical coherence tomography angiography in Alzheimer's disease. JAMA Ophthalmology. 2018. ↩︎
Alber J et al. 'Retinal optical coherence tomography features associated with incident cognitive impairment: The Mayo Clinic Study of Aging'. Neurology. 2024. ↩︎
Cheung CY et al. Retinal vascular fractals and cognitive impairment. Annals of Clinical and Translational Neurology. 2023. ↩︎
Alber J et al. Ganglion cell layer thickness predicts progression in MCI. Alzheimer's Research & Therapy. 2022. ↩︎
Zhang Y et al. 'OCT angiography findings in Alzheimer''s disease: A systematic review and meta-analysis'. Ophthalmology Retina. 2024. ↩︎
Qin Y et al. 'Choroidal thickness in Alzheimer''s disease: A meta-analysis'. Acta Ophthalmologica. 2023. ↩︎
Koronyo Y et al. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. JCI Insight. 2017. ↩︎
Murueta-Goyena A et al. 'Retinal thickness predicts disease progression in Parkinson''s disease: A longitudinal study'. Movement Disorders. 2021. ↩︎
Wang J et al. 'Optical coherence tomography angiography in Parkinson''s disease: A systematic review and meta-analysis'. Parkinsonism & Related Disorders. 2021. ↩︎
Ringelstein M et al. 'Retinal involvement in amyotrophic lateral sclerosis: A systematic review and meta-analysis'. Neurology. 2023. ↩︎
Ferrari S et al. 'Retinal abnormalities in frontotemporal dementia: A systematic review'. Journal of Neurology, Neurosurgery & Psychiatry. 2022. ↩︎
Anders S et al. 'Retinal degeneration in Huntington''s disease: Structural changes and biomarker potential'. Brain. 2022. ↩︎
Kwon YH et al. 'Retinal findings in multiple system atrophy: A prospective study'. Parkinsonism & Related Disorders. 2024. ↩︎
Lee JY et al. Retinal changes in dementia with Lewy bodies compared to Alzheimer's disease. Journal of Neurology. 2024. ↩︎
Ashraf M et al. Multi-modal retinal imaging combining OCT and plasma biomarkers for Alzheimer's disease detection. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2025. ↩︎
Lolich M et al. 'AI-based retinal analysis for Alzheimer''s disease prediction: A multi-center validation study'. NPJ Digital Medicine. 2025. ↩︎
Cheung CY et al. Retinal biomarkers as outcome measures in Alzheimer's disease clinical trials. Alzheimer's Research & Therapy. 2024. ↩︎
DeBuc DC et al. Role of retinal imaging in Alzheimer's disease clinical trials. Alzheimer's & Dementia. 2023. ↩︎
Lim JK et al. Clinical utility of retinal biomarkers in neurodegenerative disease. Journal of Alzheimer's Disease. 2024. ↩︎
Song Z et al. Challenges in retinal biomarker translation for neurodegeneration. Translational Neurodegeneration. 2024. ↩︎
Wu Y et al. Deep learning for retinal biomarker discovery in neurodegenerative diseases. Neurobiology of Disease. 2025. ↩︎
More SS et al. Hyperspectral retinal imaging for amyloid detection in Alzheimer's disease. Scientific Reports. 2025. ↩︎
Chaurasia AK et al. Adaptive optics imaging of retinal ganglion cells in neurodegenerative diseases. Biomedical Optics Express. 2024. ↩︎
Liu F et al. Ensemble deep learning for retinal-based Alzheimer's disease classification. Medical Image Analysis. 2024. ↩︎
Xue K et al. 'Portable OCT devices for neurodegenerative disease screening: Validation study'. npj Digital Medicine. 2026. ↩︎